{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:45:57Z","timestamp":1792014357227,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFA0802300"],"award-info":[{"award-number":["2019YFA0802300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of fibrosis. Liver biopsy remains the gold standard for the confirmation of fibrosis in NAFLD patients. Effective and non-invasive diagnosis of advanced fibrosis is essential to disease surveillance and treatment decisions. Herein we used routine medical test markers and logistic regression to differentiate early and advanced fibrosis in NAFLD patients from China, Malaysia, and India (<jats:italic>n<\/jats:italic><jats:sub>1<\/jats:sub> = 540, <jats:italic>n<\/jats:italic><jats:sub>2<\/jats:sub> = 147, and <jats:italic>n<\/jats:italic><jats:sub>3<\/jats:sub> = 97) who were confirmed by liver biopsy. Nine parameters, including age, body mass index, fasting blood glucose, presence of diabetes or impaired fasting glycemia, alanine aminotransferase, \u03b3-glutamyl transferase, triglyceride, and aspartate transaminase\/platelet count ratio, were selected by stepwise logistic regression, receiver operating characteristic curve (ROC), and hypothesis testing and were used for model construction. The area under the ROC curve (auROC) of the model was 0.82 for differentiating early and advanced fibrosis (sensitivity = 0.69, when specificity = 0.80) in the discovery set. Its diagnostic ability remained good in the two independent validation sets (auROC = 0.89 and 0.71) and was consistently superior to existing panels such as the FIB-4 and NAFLD fibrosis score. A web-based tool, LiveFbr, was developed for fast access to our model. The new model may serve as an attractive tool for fibrosis classification in NAFLD patients.<\/jats:p>","DOI":"10.3389\/fmed.2021.637652","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T06:36:26Z","timestamp":1614062186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Chao","family":"Sang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/s1542-3565(04)00440-9","article-title":"Non-alcoholic fatty liver disease: a review of current understanding and future impact","volume":"2","author":"Charlton","year":"2004","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e104941","DOI":"10.1371\/journal.pone.0104941","article-title":"Association between non-invasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis","volume":"9","author":"Sesti","year":"2014","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"B6","first-page":"246","article-title":"Clinical efficacy of AST\/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis","volume":"43","author":"Park","year":"2004","journal-title":"Korean J Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple non-invasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/liv.12327","article-title":"Improved fibrosis staging by elastometry and blood test in chronic hepatitis C","volume":"34","author":"Cales","year":"2014","journal-title":"Liver Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11894-015-0447-z","article-title":"A comprehensive review of non-invasive liver fibrosis tests in pediatric non-alcoholic fatty liver disease","volume":"17","author":"Mansoor","year":"2015","journal-title":"Curr Gastroenterol Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Non-invasive assessment of liver disease in patients with non-alcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ehf2.12222","article-title":"Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction","volume":"5","author":"Yoshihisa","year":"2018","journal-title":"ESC Heart Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-020-0934-0","article-title":"Human postprandial responses to food and potential for precision nutrition","volume":"26","author":"Berry","year":"2020","journal-title":"Nat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41575-020-0327-3","article-title":"Gut microbiome, big data and machine learning to promote precision medicine for cancer","volume":"17","author":"Cammarota","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2018.07.041","article-title":"Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning","volume":"35","author":"Wei","year":"2018","journal-title":"EBioMedicine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12916-020-01595-w","article-title":"Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection","volume":"18","author":"Xie","year":"2020","journal-title":"BMC Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of non-alcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12072-014-9596-7","article-title":"A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis","volume":"9","author":"Chan","year":"2015","journal-title":"Hepatol Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.cgh.2019.08.023","article-title":"Volumetric liver fat fraction determines grade of steatosis more accurately than controlled attenuation parameter in patients with non-alcoholic fatty liver disease","volume":"18","author":"Harry","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for non-alcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3760\/cma.j.issn.1007-3418.2018.03.008","article-title":"Guidelines of prevention and treatment for non-alcoholic fatty liver disease: a 2018 update","volume":"26","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/s0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejrad.2006.11.003","article-title":"Cirrhosis: CT and MR imaging evaluation","volume":"61","author":"Brancatelli","year":"2007","journal-title":"Eur J Radiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.637652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T06:36:29Z","timestamp":1614062189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.637652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":30,"alternative-id":["10.3389\/fmed.2021.637652"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.637652","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"article-number":"637652"}}